Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 30

1.

The GRACE Checklist: A Validated Assessment Tool for High Quality Observational Studies of Comparative Effectiveness.

Dreyer NA, Bryant A, Velentgas P.

J Manag Care Spec Pharm. 2016 Oct;22(10):1107-13. doi: 10.18553/jmcp.2016.22.10.1107.

2.

A call for comparative effectiveness research to learn whether routine clinical care decisions can protect from dementia and cognitive decline.

Dacks PA, Armstrong JJ, Brannan SK, Carman AJ, Green AM, Kirkman MS, Krakoff LR, Kuller LH, Launer LJ, Lovestone S, Merikle E, Neumann PJ, Rockwood K, Shineman DW, Stefanacci RG, Velentgas P, Viswanathan A, Whitmer RA, Williamson JD, Fillit HM.

Alzheimers Res Ther. 2016 Aug 20;8:33. doi: 10.1186/s13195-016-0200-3. Review.

3.

Quality of life and visual acuity outcomes in the Registry in Glaucoma Outcomes Research study.

Coleman AL, Lum FC, Gliklich RE, Velentgas P, Su Z; RiGOR Study Group.

J Comp Eff Res. 2016 Jan;5(1):99-111. doi: 10.2217/cer.15.59. Epub 2015 Dec 22.

PMID:
26691427
4.

Impact of treatment strategies for open angle glaucoma on intraocular pressure: the RiGOR study.

Coleman AL, Lum FC, Velentgas P, Su Z, Gliklich RE; RiGOR Study Group.

J Comp Eff Res. 2016 Jan;5(1):87-98. doi: 10.2217/cer.15.58. Epub 2015 Dec 22.

PMID:
26691269
5.

Practice patterns and treatment changes for open-angle glaucoma: the RiGOR study.

Coleman AL, Lum FC, Velentgas P, Su Z, Gliklich RE; RiGOR Study Group.

J Comp Eff Res. 2016 Jan;5(1):79-85. doi: 10.2217/cer.15.57. Epub 2015 Dec 22.

PMID:
26691017
6.

RiGOR: a prospective observational study comparing the effectiveness of treatment strategies for open-angle glaucoma.

Coleman AL, Lum FC, Velentgas P, Campion D, Su Z, Gliklich RE; RiGOR Study Group.

J Comp Eff Res. 2016 Jan;5(1):65-78. doi: 10.2217/cer.15.56. Epub 2015 Dec 22.

PMID:
26690903
7.

Association of sweat chloride concentration at time of diagnosis and CFTR genotype with mortality and cystic fibrosis phenotype.

McKone EF, Velentgas P, Swenson AJ, Goss CH.

J Cyst Fibros. 2015 Sep;14(5):580-6. doi: 10.1016/j.jcf.2015.01.005. Epub 2015 Feb 3.

PMID:
25660278
8.

Use of the Grace Checklist for Rating the Quality of Observational Comparative Effectiveness Research.

Dreyer NA, Bryant A, Su Z, Velentgas P.

Value Health. 2014 Nov;17(7):A732. doi: 10.1016/j.jval.2014.08.087. Epub 2014 Oct 26. No abstract available.

9.

The GRACE checklist for rating the quality of observational studies of comparative effectiveness: a tale of hope and caution.

Dreyer NA, Velentgas P, Westrich K, Dubois R.

J Manag Care Spec Pharm. 2014 Mar;20(3):301-8.

10.

Algorithms for identification of Guillain-Barré Syndrome among adolescents in claims databases.

Funch D, Holick C, Velentgas P, Clifford R, Wahl PM, McMahill-Walraven C, Gladowski P, Platt R, Amato A, Chan KA.

Vaccine. 2013 Apr 12;31(16):2075-9. doi: 10.1016/j.vaccine.2013.02.009. Epub 2013 Mar 6.

PMID:
23474311
11.

Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study.

Bowles EJ, Wellman R, Feigelson HS, Onitilo AA, Freedman AN, Delate T, Allen LA, Nekhlyudov L, Goddard KA, Davis RL, Habel LA, Yood MU, McCarty C, Magid DJ, Wagner EH; Pharmacovigilance Study Team.

J Natl Cancer Inst. 2012 Sep 5;104(17):1293-305. doi: 10.1093/jnci/djs317.

12.

A prospective observational safety study on MF59(®) adjuvanted cell culture-derived vaccine, Celtura(®) during the A/H1N1 (2009) influenza pandemic.

Reynales H, Astudillo P, de Vallière S, Hatz C, Schlagenhauf P, Rath B, Velentgas P, Fariña A, Sales-Carmona V, Groth N.

Vaccine. 2012 Oct 5;30(45):6436-43. doi: 10.1016/j.vaccine.2012.08.005. Epub 2012 Aug 15.

PMID:
22902681
13.

Risk of Guillain-Barré syndrome after meningococcal conjugate vaccination.

Velentgas P, Amato AA, Bohn RL, Chan KA, Cochrane T, Funch DP, Dashevsky I, Duddy AL, Gladowski P, Greenberg SA, Kramer JM, McMahill-Walraven C, Nakasato C, Spettell CM, Syat BL, Wahl PM, Walker AM, Zhang F, Brown JS, Platt R.

Pharmacoepidemiol Drug Saf. 2012 Dec;21(12):1350-8. doi: 10.1002/pds.3321. Epub 2012 Jul 16.

PMID:
22807266
14.

Incorporating stakeholder perspectives in developing a translation table framework for comparative effectiveness research.

Gliklich RE, Leavy MB, Velentgas P, Dreyer NA, Tunis SR, Mohr P, Messner DA, Moloney RM, Karkare SU, Dubois RW, Graff JS.

J Comp Eff Res. 2012 May;1(3):281-92. doi: 10.2217/cer.12.25.

PMID:
24237409
15.

Guillain-Barré syndrome and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data.

Sejvar JJ, Kohl KS, Gidudu J, Amato A, Bakshi N, Baxter R, Burwen DR, Cornblath DR, Cleerbout J, Edwards KM, Heininger U, Hughes R, Khuri-Bulos N, Korinthenberg R, Law BJ, Munro U, Maltezou HC, Nell P, Oleske J, Sparks R, Velentgas P, Vermeer P, Wiznitzer M; Brighton Collaboration GBS Working Group.

Vaccine. 2011 Jan 10;29(3):599-612. doi: 10.1016/j.vaccine.2010.06.003. Epub 2010 Jun 18. Review. No abstract available.

PMID:
20600491
16.

Outpatient urticaria diagnosis codes have limited predictive value for same-day influenza vaccine adverse event detection.

Moore KM, Duddy A, Lee GM, Velentgas P, Burwen DR, Platt R, Brown JS.

J Clin Epidemiol. 2010 Apr;63(4):407-11. doi: 10.1016/j.jclinepi.2009.08.002. Epub 2009 Nov 3.

PMID:
19889513
17.

Life expectancy in Gaucher disease type 1.

Weinreb NJ, Deegan P, Kacena KA, Mistry P, Pastores GM, Velentgas P, vom Dahl S.

Am J Hematol. 2008 Dec;83(12):896-900. doi: 10.1002/ajh.21305.

18.

A distributed research network model for post-marketing safety studies: the Meningococcal Vaccine Study.

Velentgas P, Bohn RL, Brown JS, Chan KA, Gladowski P, Holick CN, Kramer JM, Nakasato C, Spettell CM, Walker AM, Zhang F, Platt R.

Pharmacoepidemiol Drug Saf. 2008 Dec;17(12):1226-34. doi: 10.1002/pds.1675.

PMID:
18956428
19.

Cardiovascular risk of selective cyclooxygenase-2 inhibitors and other non-aspirin non-steroidal anti-inflammatory medications.

Velentgas P, West W, Cannuscio CC, Watson DJ, Walker AM.

Pharmacoepidemiol Drug Saf. 2006 Sep;15(9):641-52.

PMID:
16392153
20.

Severe vascular events in migraine patients.

Velentgas P, Cole JA, Mo J, Sikes CR, Walker AM.

Headache. 2004 Jul-Aug;44(7):642-51.

PMID:
15209685

Supplemental Content

Loading ...
Support Center